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Abstract
Background: The aim of this study is to summarize the design and methodology of a prospective, longitudinal,
observational cohort study to investigate how glaucoma affects patients’ quality of life and visually-related function
over a 4-year period.
Methods/Design: One hundred sixty-one (161) subjects were enrolled in this ongoing study. Patients between the ages
of 21–85 years with a minimum 2-year diagnosis of primary open-angle glaucoma, chronic primary angle-closure
glaucoma or pseudoexfoliation glaucoma were included. Each patient visited Wills Eye Hospital for a baseline visit.
Follow-up is planned for a minimum of 4 years, with annual visits. Each visit includes (1) Clinical evaluation: a slit lamp
examination, fundoscopy, intraocular pressure measurement, visual field examination, spectral domain optical coherence
tomography, Pelli-Robson Contrast Sensitivity test and the Spaeth-Richman Contrast Sensitivity test; (2) a performance
based measure: the Compressed Assessment of Ability Related to Vision; and (3) Subjective measures of vision-related
quality of life (the National Eye Institute Visual Functioning Questionnaire 25 and the Modified Glaucoma Symptom Scale).
Discussion: The results of this ongoing, prospective, longitudinal study are expected to shed light on the relationships
between clinical measures, performance-based measures and subjective measures of well-being, in order to assess
changes in the quality of life and the ability to function of patients with glaucoma over time.
Keywords: Glaucoma, Vision-related quality of life, Performance-based measures
Background
Glaucoma is a chronic neuro-degenerative disorder of the
optic nerve in which death of the retinal ganglion cells and
loss of optic nerve axons result in structural and functional
deficits. Glaucoma is the leading cause of irreversible blind-
ness worldwide and a major public health concern. Using
the United Nations’ population projections, it is estimated
that over 79 million people will be diagnosed with glau-
coma by the year 2020 and over 111.8 million by 2040 [1,
2]. Glaucoma, initially asymptomatic, is a major cause of
severe vision impairment. Advanced glaucoma can signifi-
cantly degrade a patient’s vision-related quality of life
(VRQoL) [3].
Although widely accepted as an important component of
patient health, quality of life (QoL) is seldom assessed in
daily clinical practice. This is partially due to limitations of
validated VRQoL instruments. Generic instruments that
assess overall QoL often underestimate the effects of spe-
cific domains, such as vision. Highly specific instruments-
such as glaucoma patient questionnaires-underestimate
generic aspects, such as anxiety [4]. Addressing patients’
VRQoL requires the use of scientifically valid and reliable
instruments. Even less frequently assessed is patients’
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ability to function in daily life, despite this being, along
with a QoL, their major concern. This study aims to link
subjective assessments of one’s QoL with objective mea-
sures of one’s function and glaucoma severity in order to
properly assess and address VRQoL.
There are three distinct approaches to measuring the
impact of glaucoma on individuals’ lives: 1) clinical mea-
sures (for example, visual acuity (VA), contrast sensitivity
(CS), and visual field (VF)), 2) self-reported measurements
of subjective well-being (QoL), and 3) performance-based
assessments of the ability to carry out daily activities [5, 6].
Many studies have investigated the QoL of patients with
glaucoma [7–15]. However, few have combined all three
approaches, including performance-based measures and
even fewer have utilized longitudinal designs [16–19]. One
of the major strengths of the current study is that the lon-
gitudinal design will allow for a comprehensive assessment
of QoL of patients with glaucoma over time.
This manuscript describes the design and methodology
of an ongoing, prospective, longitudinal, observational co-
hort study, which aims to investigate how glaucoma affects




The Institutional Review Board at Wills Eye Hospital ap-
proved the study procedure, which was conducted in ac-
cordance with the Declaration of Helsinki. Informed
consent was obtained from all participants. The consent
was in accordance with Health Insurance Portability and
Accountability Act (HIPAA) regulations.
Investigators in the Glaucoma Research Center reviewed
the electronic medical records of patients being cared for
by the Glaucoma Service of the Wills Eye Hospital to iden-
tify eligible patients.
One hundred sixty-one (161) patients are enrolled in
the study. Patient eligibility is determined according to
the inclusion and exclusion criteria specified in Table 1.
Patients with moderate-stage glaucoma without any other
eye diseases are included. Glaucoma is considered present
if the patient has glaucomatous optic neuropathy and char-
acteristic VF loss in at least one eye. The Disc Damage
Likelihood Scale (DDLS) is used to evaluate the extent of
optic disc damage caused by glaucoma. The DDLS gener-
ates a score from 1–10 based on the rim/disc ratio (rather
than cup/disc ratio) and the size of the optic nerve [20–24].
Patients presenting with DDLS stages 5 through 8 are eli-
gible to participate in the study. Patients with DDLS
stages 1 through 4 often do not exhibit VF loss due to
glaucoma. Patients with DDLS 9 and 10 have extensive
disc and field damage, making deterioration of the optic
rim difficult to detect and establish [24]. Due to these
reasons, stages 1 through 4 and 9 through 10 have
been excluded from the study.
To maximize enrollment and minimize attrition, partici-
pants were provided with consistent encouragement from
the Wills Eye Glaucoma ophthalmologists to participate in
this clinical research project. The longitudinal nature of the
project was thoroughly emphasized to patients during the
consenting process: patients agreed to participate for the en-
tire 4-year period of the study. Personal letters continue to
be mailed (printed in large font) to patients in order to
maintain positive, personalized contact. Additionally, the re-
searchers call patients two days before a scheduled follow-
up appointment as a reminder. Compensation is provided
for the completion of each of the five annual assessments.
Research instruments
An ocular examination and evaluation of both VRQoL
and performance-based visual functioning is performed
at each visit.
The ocular examination consists of best-corrected VA,
measurement of intraocular pressure (IOP), a slit lamp
examination of the anterior segment and a fundus examin-
ation. Patients’ current symptoms, health problems, medi-
cations, and ocular co-morbidities are also documented.
VAs (monocular and binocular) are scored by counting
how many letters can be read correctly using criteria from
the Lighthouse Early Treatment Diabetic Retinopathy Study
(ETDRS) charts. The score is then converted to a logarithm
of the minimum angle of resolution (LogMAR). IOPs are
measured using a calibrated Goldmann applanation tonom-
eter. The Humphrey 24–2 Swedish Interactive Threshold
Algorithm (SITA) Standard perimeter (Zeiss Meditec,
Dublin, CA) is used to test VF. A Cirrus optical coherence
Table 1 Inclusion and exclusion criteria for patient enrollment
Inclusion criteria
• Minimum 2-year diagnosis of primary open-angle glaucoma, primary
angle-closure glaucoma or pseudoexfoliation glaucoma
• Disc Damage Likelihood Scale stages 5 through 8 in at least one
eye with characteristic visual field loss
• Age between 21 and 85 years
• Able to understand and speak English
Exclusion criteria
• Unlikely to be available for annual ocular examination and reassessment
across a 4-year period
• Neurological or musculoskeletal diseases, including dementia that
would influence performance on activities of daily living
• Incisional eye surgery within the past 3 months
• Laser therapy within the previous month
• Any cause for visual impairment other than glaucoma
• Any medical condition which in the investigator’s opinion would
preclude the patient from providing reliable and valid data (e.g.,
cognitive impairment)
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tomography (OCT) (Zeiss Meditec, Dublin, CA) instru-
ment obtains optic-nerve head imaging for each patient.
The Pelli-Robson (PR) test and the Spaeth-Richman
Contrast Sensitivity (SPARCS) test are used to measure
contrast sensitivity. Contrast threshold is a measure of
the ability of the visual system to distinguish the bright-
ness of an object against a background. The PR is a con-
trast sensitivity test with 8 lines of horizontal capital
letters measuring central vision. Each set of three letters
on the chart becomes progressively lower in contrast
relative to the chart background. The patients are
instructed to read as far down as they can see. The chart
is mounted on a white wall with the patient sitting 1
meter in distance from the chart; the luminance of the
test is at 85 candelas/m2 (cd/m2), with the accepted
range being between 60 to 120 cd/m2 [25].
The SPARCS test is a new method of measuring con-
trast sensitivity. It is performed on any standard com-
puter with Internet access [26]. In this study, the
SPARCS test was administered on the same computer,
with standardized lighting conditions. SPARCS tests
contrast sensitivity in 5 different areas of the VF: cen-
trally and in 4 peripheral quadrants (Fig. 1). It does not
require the patient to recognize objects or letters, which
reduces the confounding effects of literacy, culture, and
intelligence as well as the effects of macular function
and VA. Correct and incorrect responses are recorded
until the contrast threshold is determined in each of the
5 testing areas.
ADREV (assessment of disability related to vision) is a
performance-based measure of vision related disability
[16]. There are 9 items included in ADREV: 1) reading
in reduced illumination 2) recognizing facial expression
3) detecting motion 4) reading signs at a distance 5)
finding large and small objects spread around a room 6)
navigating an obstacle course 7) putting a stick into
holes of different sizes 8) telephone simulation and 9)
matching socks. ADREV is the parent test for a newly
modified performance-based assessment utilizing four of
the original nine items. This instrument, the Compressed
Assessment of Ability Related to Vision (CAARV),
correlates excellently with the 9-item ADREV while
only requiring between 10 and 15 min to complete
(Table 2) [27]. The 4 CAARV items include: 1) com-
puterized motion detection 2) recognizing facial expres-
sions 3) reading street signs and 4) finding objects in a
room. Patients complete CAARV sub-tests with both
eyes open. They use their own appropriate refractive cor-
rection in order to simulate normal function. The pa-
tients complete two sub-tests in ambient lighting and
two sub-tests in a dark room. Each item is scored from 0
to 7, 7 being perfect performance. The scores are then
calculated for a total CAARV score as an aggregate of the
scores of all four sub-tests.
The NEI-VFQ-25 includes a series of 25 questions per-
taining to vision or feelings about a vision condition
(Table 3). The patients select answers among a multiple-
choice list of possible responses. The values of these an-
swers are re-coded and converted to a 0 to 100 scale so
that the lowest and highest possible scores are set at 0
and 100. Researchers average together the items within
each subscale to create 12 subscale scores and can
Fig. 1 Spaeth Richman Contrast Sensitivity Test (SPARCS). Two parallel horizontal lines and 2 parallel vertical lines intersect to create 9 boxes,
including a 5 cm rectangle in the center. Note the darkened square waves in the right upper quadrant. During a “set”, darkened square waves
randomly appear briefly in 1 of the 5 tested areas while the other 4 areas remain the same shade as the background. Contrast between the bars
and background decreases by 50 % after each cycle
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calculate an overall composite score by averaging the
subscale scores, excluding the general-health-rating
question [28].
The study also uses a modified glaucoma symptom
scale (MGSS), which includes 10 ocular complaints often
associated with glaucoma or treatment for glaucoma
(Table 4) [29]. For each eye, an initial four-level score is
generated, with one signifying a very bothersome prob-
lem and four signifying the absence of a problem. This
score is converted to a 0 to 100 scale, 0 signifying the
presence of a very bothersome problem and 100 signify-
ing the absence of a problem [29]. The final MGSS score
is an unweighted average of the responses to all 10
items, averaged between the two eyes.
Baseline measurements were collected at the time of
patient enrollment. At baseline, two VF examinations
were collected and averaged to produce a baseline value.
The patients enrolled in this study had minimum 2-year
diagnosis of glaucoma, therefore all study patients had
already underwent at least two VF examinations prior to
their baseline assessment. At the 48-month follow up,
two VFs will be conducted and compared to the baseline
values. A complete ocular examination was conducted,
in addition to CAARV, NEI-VFQ-25, Cirrus OCT,
SPARCS, PR Contrast Sensitivity, and the MGSS on pa-
tients at the baseline visit and will be repeated for follow
up visits at 12-, 24-, 36-, and 48-months.
Statistical analysis and sample size justification
Primary Outcome Variables will be divided into three
groups: 1) QoL (NEI-VFQ-25 and MGSS) 2) performance-
based measures of visual function (CAARV) and 3) Clinical
measures of vision (better and worse eye VF mean defect,
better and worse eye VA, and binocular SPARCS contrast
sensitivity). Primary Exposure/Demographic Variables
will be characterized as baseline DDLS score, age,
ethnicity, gender, type of glaucoma, and number of
medical comorbidities. Secondary Variables will be
characterized as better and worse eye IOP, treat-
ments, and duration of treatment.
All primary and secondary variables measured at base-
line will be compared using means, medians, standard
deviations, ranges or frequencies, and percentages. At
baseline, Spearman correlation coefficients will be pro-
vided for all pairs of outcome variables and demographic
variables.
In order to characterize the longitudinal trajectory of
VRQoL, clinical measures of vision, and vision-related
functioning over a 4-year period, analysis of these out-
comes will proceed in two stages. First, mixed effects lin-
ear regression will be used to model the average
trajectory of the sample. This will identify the appropri-
ate parametric forms for each outcome trajectory. The
study collects outcomes at five different timepoints over
the 4-year study period. Linear and quadratic curves will
be calculated, as well as a saturated model that treats
time as a categorical explanatory variable. This allows
for estimation of the mean outcome score for each visit.
The mixed effects model will account for correlation
among repeated measurements from the same patient.
Our goal in these analyses is to identify the most parsi-
monious model that adequately represents the shape of
the outcome trajectory over time. Ideally, a linear model
will be sufficient. It is possible, however, to imagine
scenarios where a quadratic term may be required
(e.g., initial decline followed by stabilization).
Second, because glaucoma is a disease with much sub-
ject heterogeneity, there are likely to be patients that dif-
fer from others in their experienced trajectories. MPlus
software will be used to implement Growth Curve
Mixture Modeling (GCMM) [30, 31]. This will group pa-
tients into a finite number of latent classes characterized
by differing outcome trajectories over time. The model
contains two parts: 1) the outcome model (i.e., the shape
of the trajectory within each class), which is a mixed
effects linear regression model and 2) the class probabil-
ity model, which links the probability of being in any
class with baseline exposure and demographic variables
through a logistic regression model. Results from the
initial mixed effects linear regression analysis will guide
selection of the trajectory shapes for the GCMM. Results
from the logistic regression portion of the model will
Table 2 Compressed Assessment of Ability Related to
Vision (CAARV)
1. Computerized motion detection
A large black cross against a white background on a computer screen
provides a point of fixation. While fixating on the cross, one at a time,
14 balls of different sizes and colors move diagonally across the screen
from either the right or the left side at a constant speed. Yellow, red,
or blue balls are used. The patient is asked to count the number of
moving balls. Each ball seen counts as ½ point. Highest score is 7 and
lowest score is 0.
2. Facial expression recognition
Seven full-face professional, colored photos of varying sizes and facial
expressions (angry, sad, happy, or surprised) are presented on a
computer screen at a distance of ½ meter. The patient receives one
point for recognizing the facial expression. Score ranged from 0 to 7
with 7 being the highest score.
3. Recognizing street signs
Seven written word signs ranging from large to small are read at a
distance of 4 meters. One character in each sign was changed from
familiar phrases making the word difficult to guess. For example, the
top sign reads SUGAR DANE, which is similar to the more familiar sugar
cane. The patient is instructed not to guess. One point is given for each
sign read correctly. Highest score is 7 and lowest score is 0.
4. Locating objects
Fourteen red and beige boxes of different sizes are scattered around
the testing room (4 x 2 meters). Sample boxes are shown before test
started. The patient attempts to locate the boxes while seated. Each box
found is worth ½ point. Highest score is 7 and lowest 0.
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Table 3 National Eye Institute Visual Functioning Questionnaire – 25 (NEI-VFQ-25)
1. In general, would you say that your overall health is:
1) Excellent 2) Very Good 3) Good 4) Fair 5) Poor
2. At the present time, would you say your eyesight using both eyes (with glasses or contact lenses, if you wear them) is:
1) Excellent 2) Good 3) Fair 4) Very Poor 5) Completely Blind
3. How much of the time do you worry about your eyesight?
1) None of the time 2) A little of the time 3) Some of the time 4) Most of the time 5) All of the time
4. How much pain or discomfort have you had in and around your eyes (for example, burning, itching, or aching)? Would you say it is:
1) None 2) Mild 3) Moderate 4) Severe 5) Very severe
PART 2 – Difficulty with Activities
The next questions are about how much difficulty you have doing a certain activity, for each question answer: 1) No difficulty at all, 2) A little
difficulty, 3) Moderate difficulty, 4) Extreme difficulty, 5) Stopped doing this because of eyesight, 6) Stopped doing this for other reasons or not
interested in doing this.
5. How much difficulty do you have reading ordinary print in newspapers?
6. How much difficulty do you have doing work or hobbies that require you to see well up close, such as cooking, sewing, fixing things around
the house, or using hand tools?
7. Because of your eyesight, how much difficulty do you have finding something on a crowded shelf?
8. How much difficulty do you have reading street signs or the names of stores?
9. Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night?
10. Because of your eyesight, how much difficulty do you have noticing objects off to the side while you are walking along?
11. Because of your eyesight, how much difficulty do you have seeing how people react to things you say?
12. Because of your eyesight, how much difficulty do you have picking out and matching your own clothes?
13. Because of your eyesight, how much difficulty do you have visiting with people in their homes, at parties, or in restaurants?
14. Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events?
15. Now, I’d like to ask you about driving a car. Are you currently driving, at least once in a while?
1) Yes 2) No
15a. IF NO: Have you never driven a car or have you given up driving?
1) Never drove 2) Gave up
15b. IF GAVE UP DRIVING: Was that
1) mainly because of your eyesight, 2) mainly for some other reason, 3) both your eyesight and other reasons?
15c. IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in familiar places?
16. How much difficulty do you have driving at night?
16a. How much difficulty do you have driving in difficult conditions, such as in bad weather, during rush hour, on the freeway, or in city traffic?
PART 3 – Responses to Vision Problems
The next questions are about how things you do may be affected by your vision. For each one, I’d like you to tell me if this is true for you 1) all,
2) most, 3) some, 4) a little, or 5) none of the time.
17. Do you accomplish less than you would like because of your vision?
18. Are you limited in how long you can work or do other activities because of your vision?
19. How much does pain or discomfort in or around your eyes, for example, burning, itching or aching, keep you from doing what you’d like to
be doing?
For each of the following statements, please tell me if it is 1) definitely true, 2) mostly true, 3) mostly false, or 4) definitely false for you or you are
5) not sure.
20. I stay home most of the time because of my eyesight.
21. I feel frustrated a lot of the time because of my eyesight.
22. I have much less control over what I do, because of my eyesight.
23. Because of my eyesight, I have to rely too much on what other people tell me.
24. I worry about doing things that will embarrass myself or others, because of my eyesight.
25. I need a lot of help from others because of my eyesight.
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allow for identification of baseline characteristics associ-
ated with differing changes in outcomes over time.
Models will be fit with up to five latent classes using the
Bayesian Information Criterion (BIC) to select the best-
fitting model [32].
In order to determine whether changes in VRQoL are
associated with changes in clinical measures of vision
and performance-based measures of visual function, an
extension of GCMM will be used to model to simultan-
eously model multiple outcome trajectories and identify
classes based on the joint consideration of multiple out-
comes. This will jointly model the trajectories of the pri-
mary outcome variables [32]. The resulting classes will
have differing trajectory shapes for each outcome. Based
on these results, we will be able to characterize the ways
in which these outcomes change concurrently over time
and the baseline patient characteristics that are associ-
ated with differing trajectories.
No sample size formulae exist for GCMM. A sufficient
sample size of 160 patients was chosen in order to iden-
tify subgroups using the latent class analysis. The pri-
mary goal of this analysis is to estimate parameters of
the trajectory in each class with appropriate precision.
The precision of the confidence interval will be calcu-
lated for the class- and outcome-specific slopes, assum-
ing that a linear model is sufficient to describe the
trajectory of a particular outcome. Class sizes will vary
based on outcome. For illustration, we estimated
precision for class sizes of 20, 60, and 100. Each patient
will have up to five observations. Assuming 5 %
dropout per year, the average number of observations
per patient is 4.5.
Table 5 shows the width of the confidence interval for
the slopes for NEI-VFQ-25 Total Score and LogMAR
VA. For reference, a slope of one would indicate a 12-
unit change in the NEI-VFQ over 12 months. A slope of
0.01 for LogMAR would indicate a change of 0.12 units
over 12 months. The calculations given in Table 5 as-
sume an intra-subject correlation of 0.2. Higher values
within subject correlation would result in less precision
while lower correlation would result in increased
precision.
Missing data
Based on prior studies conducted in the Wills Eye
Glaucoma Research Center, we anticipated losing ap-
proximately 5 % of enrolled patients per year (total 20 %
across 4 years) due to attrition. Both mixed effects
models and the GCMMs include all available data from
all patients under the assumption that any missing data
are missing at random. This is the approach researchers
will take for the study’s primary analysis. As a sensitivity
analysis, researchers will fit the final models using only
patients with data from all visits.
Discussion
“How can I improve, or at least maintain, the overall
health and well being of my patients?” – is one of the
most important questions every ophthalmologist should
ask himself or herself, especially when treating patients
with glaucoma.
Many visually impaired individuals have difficulty per-
forming daily activities, such as reading, writing, eating,
dressing and traveling from place to place. These diffi-
culties tend to be even more pronounced in elderly pa-
tients, who may also have cognitive decline or other
physical ailments in addition to their visual impairment.
Understanding the impact of these difficulties on an in-
dividual’s QoL and how they are able to function in their
Table 4 Modified glaucoma symptom scale
Have you experienced any of the following problems in the last
4 weeks?
(Please respond for both the left and right eye.)
a. Burning, Smarting, Stinging
Left Eye Right Eye
☐ Yes How bothersome has
it been?
☐ Yes How bothersome has
it been?
______ Very ______ Very
______ Somewhat ______ Somewhat
______ A Little ______ A Little






g. Feeling of Something in Your Eye
h. Hard to See in Daylight
i. Hard to See in Dark Place
j. Halos Around Lights






Distance from slope estimate to
the two-sided 95 % confidence
limits for the class-specific slope
NEI-VFQ
(Std. Dev = 17)
LogMAR VA
(Std. Dev = 0.2)
20 53 +/− 0.28 +/− 0.0033
60 159 +/− 0.16 +/− 0.0019
100 265 +/− 0.12 +/− 0.0014
NEI-VFQ-25 National eye instate vision function questionnaire; LogMAR VA
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daily lives is important and may have direct implication
on clinical decision-making.
VRQoL is an elusive term, the meaning of which is it
may vary widely between clinicians and their patients.
Two patients with the same degree of visual impairment
may have very different views on their VRQoL. In order
to understand the impact of visual impairment on the
ability of individuals to function, performance-based
measures have been developed [16–18, 33–39]. The
advantage of performance-based measures is that they
provide an objective measurement of a patient’s abilities
using standardized criteria. Ophthalmologists rarely
assess patients’ performance-based functional ability, as-
suming that surrogates such as subjective self-report on
well-being, VF, and VA are appropriate proxies [19, 40].
However, these proxies do not necessarily correlate with
performance-based measures; further, some may be
more important or relevant than others. Richman et al.
investigated the relationships among three methods of
assessing visual loss caused by glaucoma: (1) standard
clinical tests of vision, (2) self-reported QoL, and (3) the
ability to perform activities of daily living, which was
assessed by ADREV. They concluded that performance-
based testing and QoL evaluations were both inde-
pendently important measures of health, and although
related, were by no means the same [18].
The current study aims to investigate the complex re-
lationships between between clinical measures (e.g., VA,
IOP, VF, OCT and CS tests), performance-based mea-
sures (assessed by the CAARV), and subjective self-
reported measures (NEI-VFQ-25 and MGSS). One of
the major strengths of this study is investigation of
change in these relationships over a 4-year period. The
patients included in this study, diagnosed with
moderate-stage glaucoma, are more likely to show pro-
gression over 4 years, compared to patients with earlier
stage of the disease who were excluded from this study.
We also excluded patients with advanced disease, who
have already shown significant disease progression.
Previous studies have highlighted the importance of
binocular visual acuity and contrast sensitivity as predic-
tors of a patient’s ability to perform activities of daily
living [17].
In the current study, we used the SPARCS test to
measure contrast sensitivity, in addition to the PR test.
The SPARCS, a novel computerized-based CS test, is
able to differentiate between patients with glaucoma in
comparison to normal controls, and may have the po-
tential of becoming a useful surrogate for performance-
based measures [26].
In summary, the results of this ongoing, prospective,
longitudinal, observational cohort study are expected to
provide useful information on how patients with glau-
coma feel and function over a 4-year period. It is likely
to identify the rate of change in VRQoL and ability to
function compared with disease progression over time.
The results of this study may allow clinicians to under-
stand better how clinical measures reflect objective and
subjective measures of QoL in this patient population.
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